JP2016516054A5 - - Google Patents

Info

Publication number

JP2016516054A5

JP2016516054A5 JP2016503021A JP2016503021A JP2016516054A5 JP 2016516054 A5 JP2016516054 A5 JP 2016516054A5 JP 2016503021 A JP2016503021 A JP 2016503021A JP 2016503021 A JP2016503021 A JP 2016503021A JP 2016516054 A5 JP2016516054 A5 JP 2016516054A5

Authority

JP

Japan

Prior art keywords

amino acid

isolated polypeptide

polypeptide

acid sequence

positions

Prior art date

2014-03-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 claims 44
• 229920001184 polypeptide Polymers 0.000 claims 42
• 102000004196 processed proteins & peptides Human genes 0.000 claims 42
• 235000001014 amino acid Nutrition 0.000 claims 18
• 150000001413 amino acids Chemical group 0.000 claims 15
• 125000003275 alpha amino acid group Chemical group 0.000 claims 13
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 10
• RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 7
• 125000000539 amino acid group Chemical group 0.000 claims 7
• RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 5
• 235000012000 cholesterol Nutrition 0.000 claims 5
• 235000013477 citrulline Nutrition 0.000 claims 5
• 229960002173 citrulline Drugs 0.000 claims 5
• 239000008194 pharmaceutical composition Substances 0.000 claims 5
• 230000000694 effects Effects 0.000 claims 4
• 230000002209 hydrophobic effect Effects 0.000 claims 4
• 150000002632 lipids Chemical class 0.000 claims 4
• 125000006239 protecting group Chemical group 0.000 claims 4
• -1 aliphatic amino acid Chemical class 0.000 claims 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
• 241000124008 Mammalia Species 0.000 claims 2
• 125000001931 aliphatic group Chemical group 0.000 claims 2
• 210000004899 c-terminal region Anatomy 0.000 claims 2
• 239000000203 mixture Substances 0.000 claims 2
• 208000024891 symptom Diseases 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 208000024827 Alzheimer disease Diseases 0.000 claims 1
• 201000001320 Atherosclerosis Diseases 0.000 claims 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
• 230000002378 acidificating effect Effects 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 239000008103 glucose Substances 0.000 claims 1
• 238000002955 isolation Methods 0.000 claims 1
• 230000001404 mediated effect Effects 0.000 claims 1
• 230000002265 prevention Effects 0.000 claims 1
• 239000000126 substance Substances 0.000 claims 1